Discontinuation of tyrosine kinase inhibitor therapy: can chronic myeloid leukemia be cured?

VernacularTitle:慢性粒细胞白血病的治疗:停用酪氨酸激酶抑制剂能否带来治愈
Author: Lingyan WANG ; Jianda HU
Publication Type:Journal Article
Keywords: Leukemia,myelogenous,chronic; Imatinib; Minimal residual disease
From: Journal of Leukemia & Lymphoma 2012;21(3):129-132
CountryChina
Language:Chinese
Abstract: It is a crucial question whether it is necessary to continue the treatment after the patients with chronic myeloid leukemia (CML) who have achieved a complete molecular response (CMR) on imatinib (IM) treatment. If tyrosine kinase inhibitor (TKI) therapy was required indefinitely to maintain CMR, the problems of financial burden and adverse effects would be increased. Approximately 40 ％ of patients with a stable CMR for at least 2 years could stop IM treatment and remain in molecular remission for at least 2 years without IM treatment. Therefore, the ultimate aim should be to give the patients long-term disease control without the need for ongoing treatment. Here the studies progresses of discontinuation of TKI therapy in CML reported in the 53th American Society of Hematology (ASH) annual meeting were reviewed.